These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21900402)

  • 1. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
    Patterson AD; Maurhofer O; Beyoglu D; Lanz C; Krausz KW; Pabst T; Gonzalez FJ; Dufour JF; Idle JR
    Cancer Res; 2011 Nov; 71(21):6590-600. PubMed ID: 21900402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma fetal bile acids 7α-hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis.
    Mocan T; Kang DW; Molloy BJ; Jeon H; Spârchez ZA; Beyoğlu D; Idle JR
    Sci Rep; 2021 Apr; 11(1):8298. PubMed ID: 33859329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy.
    Ng SSW; Jang GH; Kurland IJ; Qiu Y; Guha C; Dawson LA
    EBioMedicine; 2020 Sep; 59():102973. PubMed ID: 32891936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic study of the intervention effects of Shuihonghuazi Formula, a Traditional Chinese Medicinal formulae, on hepatocellular carcinoma (HCC) rats using performance HPLC/ESI-TOF-MS.
    Bao Y; Wang S; Yang X; Li T; Xia Y; Meng X
    J Ethnopharmacol; 2017 Feb; 198():468-478. PubMed ID: 28108381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
    Ferrarini A; Di Poto C; He S; Tu C; Varghese RS; Kara Balla A; Jayatilake M; Li Z; Ghaffari K; Fan Z; Sherif ZA; Kumar D; Kroemer A; Tadesse MG; Ressom HW
    J Proteome Res; 2019 Aug; 18(8):3067-3076. PubMed ID: 31188000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice.
    Li S; Liu H; Jin Y; Lin S; Cai Z; Jiang Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2369-75. PubMed ID: 21763219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort.
    Nezami Ranjbar MR; Luo Y; Di Poto C; Varghese RS; Ferrarini A; Zhang C; Sarhan NI; Soliman H; Tadesse MG; Ziada DH; Roy R; Ressom HW
    PLoS One; 2015; 10(6):e0127299. PubMed ID: 26030804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolite profiling analysis of hepatitis B virus-induced liver cirrhosis patients with minimal hepatic encephalopathy using gas chromatography-time-of-flight mass spectrometry and ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry.
    Huang G; Xie S; Wang M; Mao D; Huang G; Huang J; Liu X; Zhang R; Xie J; Huang LJ; Cheng C; Yao F; Zhong Y; Lin L; Yao C
    Biomed Chromatogr; 2023 Jan; 37(1):e5529. PubMed ID: 36250932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma.
    Sanabria JR; Kombu RS; Zhang GF; Sandlers Y; Ai J; Ibarra RA; Abbas R; Goyal K; Brunengraber H
    HPB (Oxford); 2016 Dec; 18(12):979-990. PubMed ID: 28340971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 17. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features.
    Pabst T; Kortz L; Fiedler GM; Ceglarek U; Idle JR; Beyoğlu D
    BBA Clin; 2017 Jun; 7():105-114. PubMed ID: 28331812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel biomarkers of hepatocellular carcinoma by high-definition mass spectrometry: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry and desorption electrospray ionization mass spectrometry imaging.
    Nagai K; Uranbileg B; Chen Z; Fujioka A; Yamazaki T; Matsumoto Y; Tsukamoto H; Ikeda H; Yatomi Y; Chiba H; Hui SP; Nakazawa T; Saito R; Koshiba S; Aoki J; Saigusa D; Tomioka Y
    Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1(Suppl 1):e8551. PubMed ID: 31412144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
    Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
    Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.